Posted by Michael Wonder on 25 Oct 2024
Shionogi receives US FDA fast track designation for the novel anti-respiratory syncytial virus drug candidate S-337395
24 October 2024 - Shionogi announced that the US FDA has granted fast track designation for S-337395, our novel anti-respiratory syncytial virus (RSV) drug candidate.
S-337395 is an oral, novel anti-RSV investigational drug that targets the protein, essential for RSV replication, thereby inhibiting its proliferation.
